ALS is a progressive neurodegenerative disease that robs people of the ability to move and leads them to lose their ability to speak — and eventually breathe.1
For over a decade, Biogen has been committed to advancing ALS research to provide a deeper understanding of all forms of this devastating disease, which currently impacts an estimated 3,000 Canadians2 and 352,000 people worldwide.3,4*
By leveraging established scientific capabilities and embarking on strong R&D collaborations, we’re determined to follow the science to advance a comprehensive, multi-modality ALS portfolio that fosters our long-term leadership in this space.
Amyotrophic lateral sclerosis (ALS) is a fatal, adult-onset neurodegenerative disorder.5 Symptoms include progressive muscle weakness, paralysis and respiratory complications.6 Learn more about how the disease progresses in adults in this short video.
Biogen conducts clinical trials in ALS and other disease areas related to the investigational therapies in our pipeline to evaluate the efficacy and safety of potential medicines.
Canadians2 and 352,000 people worldwide3,4* are impacted by ALS.
Average life expectancy from time of symptom onset.7
ALS cases caused by mutations in the SOD1 gene; life expectancy in SOD1-ALS varies widely, with some patients surviving less than a year.8